S. Chittoor

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Edward S. Kim, S. Saxman, L. Schwartzberg, 2013, The Lancet. Oncology.

Adjuvant therapy in early breast cancer.

S. Swain, S. Chittoor, 1991, American Family Physician.

A planned comparison of menopausal symptoms during year 1 in patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study

J. Pippen, S. Jones, J. Blum, 2003 .

Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Edward S. Kim, S. Saxman, L. Schwartzberg, 2013, The Lancet. Oncology.

Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.

W. Berry, L. Asmar, S. Mull, 2006, Clinical genitourinary cancer.